After five years of extensive research, I am proud to share that Dr. Hasselbalch and I have published our latest article in Frontiers in Hematology this March. Our paper provides a comprehensive analysis of how cardiovascular drugs, dietary supplements, and lifestyle interventions can be leveraged to treat Polycythemia Vera and related blood disorders. In this work, we take a deep dive into the complex, underlying connections between cardiovascular disease, chronic inflammation, and blood stem cell mutations.
Paper · Front. Hematol. · 2026Revisiting old drugs and drug combinations for polycythemia vera and related neoplasmsPolycythemia Vera (PV) and related myeloproliferative neoplasms (MPNs) require long-term management to minimize thrombotic complications, disease progression, and improve quality of life. While interferon-alpha (IFN- α ) offers disease-modifying potential, disease symptoms and side effects often persist, necessitating the exploration of complementary therapeutic strategies. This review examines established drugs and…frontiersin.orgNiacin breakdown products 2PY and 4PY linked to higher cardiovascular risk (Ferrell 2024)
Summarizes Ferrell et al. 2024: untargeted metabolomics found that the niacin end-products 2PY and 4PY predict major adverse cardiac events, with 4PY promoting vascular inflammation. The link was supported by genetics (the ACMSD gene) in humans and mice, which raises questions about heavy niacin intake from food fortification.

